Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development

  • Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions
  • Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions

Preclinical Data Highlights Potential of Ikarovec's Bicistronic Gene Therapy Approach in Common Causes of Vision Loss

  • Studies presented at leading ophthalmology and gene therapy conferences demonstrate therapeutic potential in geographic atrophy and wet AMD, leading causes of legal blindness
  • This single-administration gene therapy approach could replace frequent eye injections for geographic atrophy and wet AMD patients
  • The lead candidate IKAR-001 (previously known as IKC159V) will proceed to a geographic atrophy clinical trial supported by studies showing preservation of cells critical for vision

£250k Investment to Support New Businesses in Heart Health, as 1 in 4 UK Deaths Linked to Cardiovascular Conditions

Sandwich, UK - 28 May 2025: Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.

Partnered with health-specialist venture capital firm Zinc, the initiative offers expert-led business skills sessions and the opportunity to secure £250k Zinc investment.

Selvita Acquires License for Medicines Discovery Catapult’s Patented Target Engagement Technology

Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.

MDC’s Chemical Protein Stability Assay (CPSA) is a distinctive technology used to assess target engagement. It can be applied at every step of the drug discovery process to support drug development, screening, and optimisation.

Business Continuity Planning Cheat Sheet for Labs

When it comes to unforeseen research disruptions, the most successful lab operations professionals hope for “if” but plan for “when.” Yet, a survey found that only 51% of businesses have continuity plans. Business continuity plans (BCPs) ensure labs can maintain critical functions, quickly resume normal operations, and prevent the loss of valuable research in the event of interruptions. This guide explores why and how to create a business continuity plan for your laboratory.

Maxion Therapeutics doubles R&D space at Unity Campus after £58 million Series A fundraise

•    Maxion Therapeutics expands its Cambridge headquarters and doubles the size of its offices and laboratory space
•    Howard Group provides tailored real estate solution to support the biotech’s growth

Cambridge, 20th May 2025: Leading regional property investor and developer Howard Group, is delighted to announce that pioneering biotechnology company Maxion Therapeutics has more than doubled its footprint at Unity Campus.

Subscribe to